Abstract
A set of hydroxamate derivatives of folic acid and methotrexate (MTX) was synthesized and evaluated for the inhibitory activity against histone deacetylase (HDAC) and dihydrofolate reductase (DHFR), two enzymes overexpressed in metastasizing tumors. The synthesized compounds were further screened for their antiproliferative activity in two human cancer cell lines, A549 (non-small cell lung carcinoma) and PC-3 (prostate adenocarcinoma). All derivatives showed significant inhibitory activity against HDACs (micromolar range) while only the MTX derivative was reasonably effective in DHFR inhibition. A docking study provided insight into the binding mode of the most potent inhibitor in the active sites of the enzymes, allowing rationalization of the bioassays. The MTX-based compound could be of interest for testing against metastasizing tumors in an animal model. The studied derivatives represent promising molecular templates for further development of dual activity anti-cancer drugs.
Keywords: Antiproliferative, cancer therapy, dihydrofolate reductase inhibitors, dual enzyme inhibitors, folates and antifolates, histone deacetylase inhibitors, methotrexate, Folate-Hydroxamate, Antimetabolites
Medicinal Chemistry
Title: Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Volume: 7 Issue: 4
Author(s): Marta P. Carrasco, Eva A. Enyedy, Natalia I. Krupenko, Sergey A. Krupenko, Elisa Nuti, Tiziano Tuccinardi, Salvatore Santamaria, Armando Rossello, Adriano Martinelli and M. Amelia Santos
Affiliation:
Keywords: Antiproliferative, cancer therapy, dihydrofolate reductase inhibitors, dual enzyme inhibitors, folates and antifolates, histone deacetylase inhibitors, methotrexate, Folate-Hydroxamate, Antimetabolites
Abstract: A set of hydroxamate derivatives of folic acid and methotrexate (MTX) was synthesized and evaluated for the inhibitory activity against histone deacetylase (HDAC) and dihydrofolate reductase (DHFR), two enzymes overexpressed in metastasizing tumors. The synthesized compounds were further screened for their antiproliferative activity in two human cancer cell lines, A549 (non-small cell lung carcinoma) and PC-3 (prostate adenocarcinoma). All derivatives showed significant inhibitory activity against HDACs (micromolar range) while only the MTX derivative was reasonably effective in DHFR inhibition. A docking study provided insight into the binding mode of the most potent inhibitor in the active sites of the enzymes, allowing rationalization of the bioassays. The MTX-based compound could be of interest for testing against metastasizing tumors in an animal model. The studied derivatives represent promising molecular templates for further development of dual activity anti-cancer drugs.
Export Options
About this article
Cite this article as:
P. Carrasco Marta, A. Enyedy Eva, I. Krupenko Natalia, A. Krupenko Sergey, Nuti Elisa, Tuccinardi Tiziano, Santamaria Salvatore, Rossello Armando, Martinelli Adriano and Amelia Santos M., Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation, Medicinal Chemistry 2011; 7 (4) . https://dx.doi.org/10.2174/157340611796150923
DOI https://dx.doi.org/10.2174/157340611796150923 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Polymorphism of miR-218-2 (rs11134527) in Cervical Cancer: A
Case-Control Study on the Bangladeshi Women
MicroRNA Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences Various Müllerian-duct Anomalies in Women at Rural Tertiary Care Center of Northern India: An Observational Study
Current Women`s Health Reviews Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Topoisomerase I-DNA Complex Stability Induced by Camptothecins and Its Role in Drug Activity&#
Current Medicinal Chemistry - Anti-Cancer Agents Epothilones: A Novel Class of Non-taxane Microtubule-stabilizing Agents
Current Pharmaceutical Design Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells
Current Molecular Pharmacology A Simple Identification of Novel Carbonyl Reducing Enzymes in the Metabolism of the Tobacco Specific Carcinogen NNK
Drug Metabolism Letters Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology